S/N 09/732,241

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Mathai Mammen et al.

Serial No.:

09/732,241

Filed:

December 7, 2000

Title:

THERAPEUTIC CARBAMATES

RECEIVED

Suppl Prior

Examiner: Raymond Covington

Froup Art Unit: 1625

Docket: 1343.011US1

SEP 0 4 2002

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

TECH CENTER 1600/290

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(2), Applicants have included the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p). Please charge any additional fees or credit any overpayment to Account No. 19-0743.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

08/30/2002 SSESHE1 00000039 09732241

01 FC:126

180.00 09

MATHAI MAMMEN ET AL.

COPY OF PAPERS ORIGINALLY FILED

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 359-3265

Robert I Harris Ph D

Robert J. Harris, Ph.D. Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this day of August, 2002.

Name \) Quy III. Yoole

Signature

PTO/SB/08A(10-01)
Approved for uso through 10/31/2002. OMB 651-0031
Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE

ubstitute for form 1449A/PTO NFORMATION DISCLOSURE	Complete if Known			
STATEMENT BY APPLICANT (Use as many sheets as necessary)	Application Number	09/732241		
	Filing Date	December 7, 2000		
	First Named Inventor	Mammen, Mathai	1000	
	Group Art Unit	1614	•	
	Examiner Name	Unknown	AUS 2 9 2002	
Sheet 1 of 1	Attorney Docket No: 0	01343.011US1		

US PATENT DOCUMENTS						
Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
	US-5621010	04/15/1997	Sueda, N., et al	514	596	05/18/1994

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²

	OTHE	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		TAKEUCHI, MAKOTO.,et al., "Preparation of heterocyclyl carbomate derivatives with muscarine M3 receptor antagonism", Retrieved from STN Database Accession No. 123:285789, (March 9, 1995),	

COPY OF PAPERS ORIGINALLY FILED RECEIVED

SEP 0 4 2002

TECH CENTER 160012900

1343. DIDNO1